Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Controversies in the Management of Early-Stage Hodgkin Lymphoma: The Role of Radiation Therapy. (PubMed, J Natl Compr Canc Netw) - "Meanwhile, novel agents such as nivolumab and brentuximab vedotin have significantly advanced the treatment of advanced-stage disease and are now demonstrating promising activity in early-stage Hodgkin lymphoma. Techniques such as proton therapy, intensity-modulated RT, and image-guided RT dramatically reduce radiation exposure to healthy tissues compared with historical approaches, thereby improving the therapeutic ratio. Despite the high cure rates achieved today, clinical trials continue to explore novel and personalized approaches to achieve long-term remission without compromising quality of life."

Journal • Review • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. (PubMed, Blood Cancer J) - P3 | "ClinicalTrials.gov number: NCT01777152."

Journal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Anaplastic Large Cell Lymphoma

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. (PubMed, Lancet Haematol) - P1/2 | "Our data suggest that dose-dense BV-ICE is a rapidly administered and active salvage regimen for patients with relapsed or refractory classical Hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target. Although cross-trial comparisons should be made with caution, activity results seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations delivered over much longer durations and can be considered in young (<60 years), transplantation-eligible patients for second-line therapy."

Clinical • Journal • P1/2 data • Bone Marrow Transplantation • Cardiovascular • Diabetes • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Thrombocytopenia • Transplantation

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology (ICML 2023) - P2 | "Except for brentuximab vedotin in CD30-positive disease, agents were generally approved based on overall response rates (ORR) of less than 30%. The ORR (by IRC) of DUV was higher in pts with PTCL-NOS (48%) and AITL (67%), compared with ALCL (13%). This corresponded to a longer median PFS of 3.5 mo in PTCL-NOS and 9.1 mo in AITL compared with 1.5 mo in ALCL. Although not powered for subset analyses, this analysis suggests activity of DUV may not be uniform across different types of lymphomas."

Clinical • P2 data • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CD4 • PIK3CG • TNFRSF8

Brentuximab vedotin-associated rash – case report of an exanthem with (potentially) prognostic significance (ADO 2026) - No abstract available

Case report • Clinical • Hematological Malignancies • Lymphoma • Oncology

Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826 (ASH 2025) - "In the S1826 phase III trial, patients (pts) with newlydiagnosed advanced stage cHL who were treated with nivolumab (N)-AVD, vs brentuximab-vedotin (BV)-AVD, had improved progression-free survivals (PFS), establishing a new standard of care. In S1826, ctDNA-guided analyses of MTB enabled early risk stratification at C3D1 andstrongly outperformed PET assessments at EOT. Future prospective studies should incorporate ctDNAanalyses of MTB to improve precision therapy in cHL."

Circulating tumor DNA • Clinical • IO biomarker • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial (ASH 2023) - P3 | "INTRODUCTION The GHSG-HD21 trial for newly diagnosed adult patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) compares the BrECADD regimen (Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar­bazine, prednisone) in a PET adapted approach. Importantly, while the larger patient cohort of PET2-negative patients achieves a very high 3-yr PFS of 97% with a very short and safe 12-week treatment, this benefit was also observed for PET2-positive patients. In conclusion, the optimized risk-benefit ratio of the BrECADD regimen combined with the individualized PET2-guided treatment duration sets a new benchmark for the treatment of adult patients with newly diagnosed advanced stage cHL"

P3 data • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lymphoma • Oncology • Thrombocytopenia

First-Line Treatment Patterns and Outcomes in Older Patients With Hodgkin Lymphoma in a Resource-Limited Setting: A Real-World Retrospective Single-Center Study (SOHO 2026) - "Five patients received the AEVD regimen (doxorubicin hydrochloride [Adriamycin], etoposide, vinblastine, and dacarbazine), of whom 3 were alive and disease-free at the time of analysis; outcome data for the remaining 2 patients were unavailable. This real-world experience suggests that bleomycin-sparing approaches, even without newer agents, are feasible in older patients with Hodgkin lymphoma and may offer a pragmatic treatment option in routine practice. In the absence of access to nivolumab or brentuximab vedotin, etoposide-based regimens could serve as a reasonable alternative. Larger prospective studies are warranted to better define optimal treatment strategies for this vulnerable population."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. (ASCO 2022) - P3 | "In ECHELON-1 (NCT01712490), 5-year follow-up analyses supported the long-term progression-free survival (PFS) benefit with first-line brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients (pts) with stage III/IV cHL, independent of interim positron emission tomography status. A+AVD treatment resulted in a statistically significant 41% reduction in the risk of death vs ABVD, with a manageable safety profile consistent with prior reports. These outcomes confirm A+AVD as a preferred option for pts with previously untreated stage III/IV cHL."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain

Staphylococcus Aureus Infection Mimicking Brentuximab Vedotin Resistance in Transformed Mycosis Fungoides (SOHO 2026) - "He was treated with intravenous vancomycin and underwent total knee arthroplasty revision followed by a 6-week course of daptomycin and rifampin. Early recognition of infection-driven flares may prevent unnecessary escalation of systemic therapy and improve patient outcomes. IL: interleukin, JAK: Janus kinase, PET: positron emission tomography, STAT: signal transducer and activator of transcription."

Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma • IL10 • STAT3 • TNFRSF8

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial. (PubMed, Hemasphere) - No abstract available

Journal • Monotherapy • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASTRO 2025) - "16 (89%) received doxorubicin/hydroxydaunorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the three patients currently in remission included pembro plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1)... Pembro-RT yielded excellent CMR rates and minimal toxicity. These data suggest pembro-RT as a potential alternative to high dose chemo and SCT in localized, favorable relapsed/refractory HL. Enrollment to the study is complete and data will be updated prior to the meeting."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

2-YEAR FOLLOW-UP OF THE S1826 STUDY CONFIRMS IMPROVED PROGRESSION-FREE SURVIVAL WITH NIVOLUMAB-AVD COMPARED TO BRENTUXIMAB VEDOTIN-AVD IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA (ISHL 2024) - "We hypothesized that introducing PD-1 blockade with nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) would improve progression-free survival (PFS) over BV-AVD in AS cHL and evaluated this approach in the randomized, phase 3 S1826 study. N-AVD was better tolerated and improved PFS versus BV-AVD in adolescent and adult pts with AS cHL. Longer follow-up confirmed the PFS benefit with N-AVD at 2 y, including pre-specified subgroups. N-AVD is a new standard of care for treatment of AS cHL."

Metastases • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Pediatrics • Pneumonia

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. (PubMed, Haematologica) - P1/2 | "ORR for cHL patients in the exploratory cohort, most of whom had relapsed after both brentuximab vedotin and ASCT, was 80% (35% CR). Combination therapy with TEM/LEN was feasible and demonstrated encouraging activity in heavily-pretreated lymphomas, particularly in relapsed/refractory cHL. ClinicalTrials.gov identifier: NCT01076543."

Clinical • Journal • P1/2 data • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immune Modulation • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial" (ASH 2022) - P2 | "From April 2018 to October 2019, 71 pts with PTCL (47 males, 24 females) were enrolled. Central pathology review according to 2017 WHO criteria found nodal TFH-PTCL (34; 47.9%) [including AITL (27; 38%) and other nodal PTCL-TFH (7; 9.9%)]; ALK- ALCL (14; 27%); PTCL-NOS (9; 13%); ALK+ ALCL (5; 7%), EATL (2; 2.8%) and other entities (7; 9.9%). Median age was 66 years (20-79), 65 pts (91.6%) were stage III-IV."

Clinical • P2 data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8

Clinical Outcomes of PD-1/PD-L1 Inhibitors in Hematologic Malignancies: A Systematic Review Across Lymphoma, Leukemia, and Multiple Myeloma (SOHO 2026) - "Studies evaluating PD-1/PD-L1 inhibitors, including nivolumab, pembrolizumab, durvalumab, and atezolizumab, in lymphoma, leukemia, and MM were reviewed...In frontline advanced-stage cHL, nivolumab combined with AVD demonstrated improved PFS compared with brentuximab vedotin plus AVDin the SWOGS1826 trial... PD-1/PD-L1 inhibitors have significantly improved outcomes in cHL and continue to show potential in selected NHL subtypes. In contrast, their role in MM remains limited because of safety concerns and reduced efficacy, while data in leukemia are still evolving. Further studies are needed to better define the role of checkpoint inhibitors and combination immunotherapy strategies across different hematologic malignancies."

Clinical • Clinical data • Review • B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mediastinal B Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Prognostic Value of Soluble CD30 and CD163+ Tumor-Associated Macrophages in Relapsed Classical Hodgkin Lymphoma: Could It Guide Treatment Choice? (SOHO 2026) - "Context: Brentuximab vedotin (BV) alone or in combination is a standard of care in relapsed classical Hodgkin lymphoma (cHL); however, BV resistance is common...Design: Prospective cohort of 120 relapsed cHL patients (BV naïve) treated with ifosfamide, carboplatin, etoposide (ICE)+BV salvage, then planned for ASCT and BV maintenance between 2021 and 2024... High sCD30 and CD163+ macrophage infiltration predicted response, transplant eligibility, and survival in relapsed cHL treated with ICE+BV, as they could limit antibody-drug conjugate delivery and promote resistance. These patients may benefit from addition of programmed cell death protein-1 (PD-1) inhibitors to BV rather than chemotherapy."

IO biomarker • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • CD163 • TNFRSF8

High efficacy and durability of second-line therapy with pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma (ISHL 2022) - "36 pts proceeded to HDT/AHCT of whom 13 (36%) received post-transplant brentuximab vedotin (BV) (n=12) or BV plus nivolumab (bv/nivo) (n=1) maintenance. Second-line therapy with P-GVD is highly effective and efficiently bridges pts with RR cHL to HDT/AHCT. With extended follow-up for transplanted pts, remissions remain durable with estimated 30-month PFS of 96%. Among 68 evaluable pts enrolled onto parts I and II, CR rate remains high at 92.6%."

Clinical • P2 data • Anemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Inflammation • Lymphoma • Mucositis • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. (PubMed, J Clin Oncol) - P2 | "Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT."

Clinical • Journal • P2 data • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mucositis • Neutropenia • Oncology • Transplantation • FDG PET

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers. (PubMed, Eur J Haematol) - P | "BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. In Ya&A with high-risk cHL, our data suggest that a BV-driven strategy (without bleomycin and consolidation radiotherapy) is an effective up-front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500."

Journal • Cardiovascular • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain

Less Is More: Complete Metabolic Response With Low-Dose Nivolumab as Bleomycin Replacement for Stage 4 Classical Hodgkin Lymphoma (SOHO 2026) - "Brentuximab vedotin and standard-dose nivolumab (200 mg)—now preferred frontline substitutes—remain financially inaccessible in resource-limited settings. To our knowledge, this is the first reported case of low-dose nivolumab as a bleomycin substitute driven simultaneously by toxicity and affordability, a dual indication unrepresented in existing trials, warranting prospective validation. ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; AVD: doxorubicin, vinblastine, dacarbazine; cHL: classical Hodgkin lymphoma; CKD: chronic kidney disease; CR: complete response; ORR: objective response rate; PET-CT: positron emission tomography and computed tomography; PD-1: programmed cell death protein."

Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2. (PubMed, Blood Adv) - P3 | "The double blind randomized phase 3 ECHELON-2 study (NCT01777152) demonstrated an improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). PFS results favored the use of SCT in both ALK-negative ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30-positive PTCL who achieve a CR following treatment with A+CHP."

Journal • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK • TNFRSF8

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

Treatment response to brentuximab vedotin in CTCL after skin, lymph node and blood involvement (ADO 2026) - "Sponsored by Takeda Pharma Vertrieb GmbH & Co. KG"

Cutaneous T-cell Lymphoma

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients. (PubMed, Hemasphere) - No abstract available

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology